Modality
Bispecific Ab
MOA
BTKi
Target
Tau
Pathway
DDR
Ovarian CaADHD
Development Pipeline
Preclinical
~Mar 2015
→ ~Jun 2016
Phase 1
~Sep 2016
→ ~Dec 2017
Phase 2
~Mar 2018
→ ~Jun 2019
Phase 3
Sep 2019
→ Jan 2027
Phase 3Current
NCT07329032
1,365 pts·Ovarian Ca
2020-04→2027-01·Active
NCT07269321
2,401 pts·Ovarian Ca
2019-09→2025-07·Recruiting
3,766 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-258mo agoPh3 Readout· Ovarian Ca
2027-01-2110mo awayPh3 Readout· Ovarian Ca
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P3
Recruit…
P3
Active
Catalysts
Ph3 Readout
2025-07-25 · 8mo ago
Ovarian Ca
Ph3 Readout
2027-01-21 · 10mo away
Ovarian Ca
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07329032 | Phase 3 | Ovarian Ca | Active | 1365 | HAM-D |
| NCT07269321 | Phase 3 | Ovarian Ca | Recruiting | 2401 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Lisorapivir | Takeda | Preclinical | WRN |